ZYDUSLIFE Zydus Lifesciences Q2 FY26 results (Jul–Sep 2025) and concall
Zydus Lifesciences delivered a strong Q2 FY26, reporting 17% YoY revenue growth and a 32.9% EBITDA margin, driven by robust performance across US, India, and international markets. The company completed key acquisitions in MedTech and consumer wellness, while advancing its specialty pipeline with Saroglitazar and CUTX-101. Management highlighted plans for deleveraging and strategic M&A, alongside addressing the impact of declining Revlimid sales.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 9.5%, net profit up 46.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 +10% |
| EBITDA | 942 | 648 | 3,773 | 585 | 1,152 +22% |
| Net profit | 790 | 471 | 2,814 | 385 | 1,157 +46% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
